Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT04340908

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Hongchang Guo (from the registry)
Registry
  • NCT NCT04340908
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04340908. Randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery
Condition
Diabetes Mellitus, Type 2
Condition
Cardiac Surgery
Intervention (Drug)
Dapagliflozin 10 MG
Intervention (Drug)
Placebos
Lead sponsor
Hongchang Guo (class: other)

Record details

Record id
cardio:ct-nct04340908
Content hash
3353fcc1548755ebbe1b9c95832b3e34abb8e7d9390510b8439e112851866a12